FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123255669> ?p ?o ?g. }

• W3123255669 endingPage "196" @default.
• W3123255669 startingPage "184" @default.
• W3123255669 abstract "The HIV protease inhibitor nelfinavir is currently being analyzed for repurposing as an anticancer drug for many different cancers because it exerts manifold off-target protein interactions, finally resulting in cancer cell death. Xenosensing pregnane X receptor (PXR), which also participates in the control of cancer cell proliferation and apoptosis, was previously shown to be activated by nelfinavir; however, the exact molecular mechanism is still unknown. The present study addresses the effects of nelfinavir and its major and pharmacologically active metabolite nelfinavir hydroxy-<i>tert</i>-butylamide (M8) on PXR to elucidate the underlying molecular mechanism. Molecular docking suggested direct binding to the PXR ligand-binding domain, which was confirmed experimentally by limited proteolytic digestion and competitive ligand-binding assays. Concentration-response analyses using cellular transactivation assays identified nelfinavir and M8 as partial agonists with EC₅₀ values of 0.9 and 7.3 µM and competitive antagonists of rifampin-dependent induction with IC₅₀ values of 7.5 and 25.3 µM, respectively. Antagonism exclusively resulted from binding into the PXR ligand-binding pocket. Impaired coactivator recruitment by nelfinavir as compared with the full agonist rifampin proved to be the underlying mechanism of both effects on PXR. Physiologic relevance of nelfinavir-dependent modulation of PXR activity was investigated in respectively treated primary human hepatocytes, which showed differential induction of PXR target genes and antagonism of rifampin-induced ABCB1 and CYP3A4 gene expression. In conclusion, we elucidate here the molecular mechanism of nelfinavir interaction with PXR. It is hypothesized that modulation of PXR activity may impact the anticancer effects of nelfinavir. <h3>SIGNIFICANCE STATEMENT</h3> Nelfinavir, which is being investigated for repurposing as an anticancer medication, is shown here to directly bind to human pregnane X receptor (PXR) and thereby act as a partial agonist and competitive antagonist. Its major metabolite nelfinavir hydroxy-<i>tert</i>-butylamide exerts the same effects, which are based on impaired coactivator recruitment. Nelfinavir anticancer activity may involve modulation of PXR, which itself is discussed as a therapeutic target in cancer therapy and for the reversal of chemoresistance." @default.
• W3123255669 created "2021-02-01" @default.
• W3123255669 creator A5006295410 @default.
• W3123255669 creator A5022577737 @default.
• W3123255669 creator A5028915250 @default.
• W3123255669 creator A5033152934 @default.
• W3123255669 creator A5041932611 @default.
• W3123255669 creator A5057183308 @default.
• W3123255669 creator A5081007016 @default.
• W3123255669 date "2021-01-22" @default.
• W3123255669 modified "2023-10-02" @default.
• W3123255669 title "Nelfinavir and Its Active Metabolite M8 Are Partial Agonists and Competitive Antagonists of the Human Pregnane X Receptor" @default.
• W3123255669 cites W1527827101 @default.
• W3123255669 cites W1606705306 @default.
• W3123255669 cites W1936123857 @default.
• W3123255669 cites W1968535758 @default.
• W3123255669 cites W1971371724 @default.
• W3123255669 cites W1986191025 @default.
• W3123255669 cites W2003599782 @default.
• W3123255669 cites W2005674716 @default.
• W3123255669 cites W2009296655 @default.
• W3123255669 cites W2012104309 @default.
• W3123255669 cites W2019702920 @default.
• W3123255669 cites W2021748188 @default.
• W3123255669 cites W2029562489 @default.
• W3123255669 cites W2034535492 @default.
• W3123255669 cites W2051783184 @default.
• W3123255669 cites W2058029975 @default.
• W3123255669 cites W2061783580 @default.
• W3123255669 cites W2063203910 @default.
• W3123255669 cites W2064259517 @default.
• W3123255669 cites W2067386680 @default.
• W3123255669 cites W2085199878 @default.
• W3123255669 cites W2088632292 @default.
• W3123255669 cites W2089270738 @default.
• W3123255669 cites W2089708610 @default.
• W3123255669 cites W2090472200 @default.
• W3123255669 cites W2096328589 @default.
• W3123255669 cites W2097675898 @default.
• W3123255669 cites W2100133674 @default.
• W3123255669 cites W2103610164 @default.
• W3123255669 cites W2106154817 @default.
• W3123255669 cites W210743834 @default.
• W3123255669 cites W2108859534 @default.
• W3123255669 cites W2110506701 @default.
• W3123255669 cites W2111016870 @default.
• W3123255669 cites W2126462108 @default.
• W3123255669 cites W2130479394 @default.
• W3123255669 cites W2132083523 @default.
• W3123255669 cites W2146254151 @default.
• W3123255669 cites W2148398630 @default.
• W3123255669 cites W2150555063 @default.
• W3123255669 cites W2155608888 @default.
• W3123255669 cites W2161179748 @default.
• W3123255669 cites W2215024593 @default.
• W3123255669 cites W2253979579 @default.
• W3123255669 cites W2309728149 @default.
• W3123255669 cites W233698158 @default.
• W3123255669 cites W2341554061 @default.
• W3123255669 cites W2440678254 @default.
• W3123255669 cites W2487757405 @default.
• W3123255669 cites W2589507128 @default.
• W3123255669 cites W2596241521 @default.
• W3123255669 cites W2748933803 @default.
• W3123255669 cites W2757088049 @default.
• W3123255669 cites W2785569423 @default.
• W3123255669 cites W2953542772 @default.
• W3123255669 cites W2954360754 @default.
• W3123255669 cites W2955962371 @default.
• W3123255669 doi "https://doi.org/10.1124/molpharm.120.000116" @default.
• W3123255669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33483427" @default.
• W3123255669 hasPublicationYear "2021" @default.
• W3123255669 type Work @default.
• W3123255669 sameAs 3123255669 @default.
• W3123255669 citedByCount "6" @default.
• W3123255669 countsByYear W31232556692021 @default.
• W3123255669 countsByYear W31232556692022 @default.
• W3123255669 countsByYear W31232556692023 @default.
• W3123255669 crossrefType "journal-article" @default.
• W3123255669 hasAuthorship W3123255669A5006295410 @default.
• W3123255669 hasAuthorship W3123255669A5022577737 @default.
• W3123255669 hasAuthorship W3123255669A5028915250 @default.
• W3123255669 hasAuthorship W3123255669A5033152934 @default.
• W3123255669 hasAuthorship W3123255669A5041932611 @default.
• W3123255669 hasAuthorship W3123255669A5057183308 @default.
• W3123255669 hasAuthorship W3123255669A5081007016 @default.
• W3123255669 hasBestOaLocation W31232556691 @default.
• W3123255669 hasConcept C104317684 @default.
• W3123255669 hasConcept C109650736 @default.
• W3123255669 hasConcept C1292079 @default.
• W3123255669 hasConcept C132040763 @default.
• W3123255669 hasConcept C142462285 @default.
• W3123255669 hasConcept C150194340 @default.
• W3123255669 hasConcept C181199279 @default.
• W3123255669 hasConcept C185592680 @default.
• W3123255669 hasConcept C203014093 @default.
• W3123255669 hasConcept C2781160516 @default.
• W3123255669 hasConcept C2993143319 @default.

• next